Involvement of Tumor Necrosis Factor Alpha and Interleukin-1β in Enhancement of Pentylenetetrazole-Induced Seizures Caused byShigella dysenteriae

ABSTRACT Neurologic manifestations, mainly convulsions, are the most frequent extraintestinal complications of shigellosis. We used an animal model to study the roles of tumor necrosis factor alpha (TNF-α) and interleukin-1 β (IL-1β) inShigella-related seizures. Administration of Shigella dysenteriae 60R sonicate enhanced the sensitivity of mice to the proconvulsant pentylenetetrazole (PTZ) within 7 h. This was indicated by a significantly higher mean convulsion score and an increased number of mice responding with clonic-tonic seizures in theShigella-pretreated group. Preinjection of mice with anti-murine TNF-α (anti-mTNF-α) or anti-murine IL-1β (anti-mIL-1β) 30 min prior to administration of Shigellasonicate abolished their enhanced response to PTZ at 7 h. Mean convulsion scores were reduced by anti-mTNF-α from 1.2 to 0.8 (P = 0.017) and by anti-mIL-1β from 1.3 to 0.7 (P = 0.008). Preinjection of anti-mTNF-α also reduced the percentage of mice responding with clonic-tonic seizures, from 48 to 29% (P = 0.002), and preinjection of anti-mIL-1β reduced it from 53 to 21% (P = 0.012). Neutralization of TNF-α or IL-1β did not protect the mice from death due to S. dysenteriae 60R. These findings indicate that TNF-α and IL-1β play a role in the very early sensitization of the central nervous system to convulsive activity after S. dysenteriae administration. Similar mechanisms may trigger neurologic disturbances in other infectious diseases.

[1]  A. Goren,et al.  Lethal toxic encephalopathy due to childhood shigellosis in a developed country. , 1992, Pediatrics.

[2]  J. Howard Observations on the intoxication produced in mice and rabbits by the neurotoxin of Shigella shigae. , 1955, British journal of experimental pathology.

[3]  B. Fredholm,et al.  Long‐term Treatment with some Methylxanthines Decreases the Susceptibility to Bicuculline‐ and Pentylenetetrazol‐induced Seizures in Mice. Relationship to c‐ios Expression and Receptor Binding , 1996, The European journal of neuroscience.

[4]  H. Merritt,et al.  Convulsive disorders , 1982, Brain and Development.

[5]  W. Scheld,et al.  Recombinant human interleukin-1 induces meningitis and blood-brain barrier injury in the rat. Characterization and comparison with tumor necrosis factor. , 1991, The Journal of clinical investigation.

[6]  J. Andersson,et al.  Cytokine secretion in acute shigellosis is correlated to disease activity and directed more to stool than to plasma. , 1995, The Journal of infectious diseases.

[7]  S. Yoshida,et al.  Magnetic resonance imaging and histopathological study of brain lesions in rabbits given intravenous verotoxin 2 , 1996, Infection and immunity.

[8]  P. López-Jaramillo,et al.  The L-arginine: nitric oxide pathway. , 1993, Current opinion in nephrology and hypertension.

[9]  P. Sansonetti,et al.  Acute inflammation causes epithelial invasion and mucosal destruction in experimental shigellosis , 1994, The Journal of experimental medicine.

[10]  M. P. Jackson,et al.  Shiga toxin: biochemistry, genetics, mode of action, and role in pathogenesis. , 1992, Current topics in microbiology and immunology.

[11]  L. Ehrlich,et al.  Interleukin-1 and tumor necrosis factor-alpha synergistically mediate neurotoxicity: involvement of nitric oxide and of N-methyl-D-aspartate receptors. , 1995, Brain, behavior, and immunity.

[12]  Abraham Weizman,et al.  An animal model for the study of neurotoxicity of bacterial products and application of the model to demonstrate that Shiga toxin and lipopolysaccharide cooperate in inducing neurologic disorders. , 1995, The Journal of infectious diseases.

[13]  R. Weitz,et al.  [Convulsions in childhood shigellosis]. , 1984, Harefuah.

[14]  F. Scheutz,et al.  The role of lipopolysaccharide and Shiga-like toxin in a mouse model of Escherichia coli O157:H7 infection. , 1997, The Journal of infectious diseases.

[15]  G. Kollias,et al.  Spontaneous inflammatory demyelinating disease in transgenic mice showing central nervous system-specific expression of tumor necrosis factor alpha. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[16]  H. Dupont,et al.  The relation between production of cytotoxin and clinical features in shigellosis. , 1986, The Journal of infectious diseases.

[17]  S. Yoshida,et al.  Direct evidence of neuron impairment by oral infection with verotoxin-producing Escherichia coli O157:H- in mitomycin-treated mice , 1994, Infection and immunity.

[18]  M. Rosenblum,et al.  Recombinant human TNF-alpha: preclinical studies and results from early clinical trials. , 1992, Immunology series.

[19]  W. Banks,et al.  Murine tumor necrosis factor alpha is transported from blood to brain in the mouse , 1993, Journal of Neuroimmunology.

[20]  V. L. Tesh,et al.  Differentiation-associated toxin receptor modulation, cytokine production, and sensitivity to Shiga-like toxins in human monocytes and monocytic cell lines , 1996, Infection and immunity.

[21]  S. Ashkenazi,et al.  Hallucinations as an initial manifestation of childhood shigellosis. , 1989, The Journal of pediatrics.

[22]  I. Clark,et al.  Malaria mimicry with tumor necrosis factor. Contrasts between species of murine malaria and Plasmodium falciparum. , 1992, The American journal of pathology.

[23]  T. Barrett,et al.  Bacterial endotoxin both enhances and inhibits the toxicity of Shiga-like toxin II in rabbits and mice , 1989, Infection and immunity.

[24]  Steven F. Maier,et al.  Immune activation: the role of pro-inflammatory cytokines in inflammation, illness responses and pathological pain states , 1995, Pain.

[25]  O. Ramilo,et al.  Cerebrospinal fluid interleukin 1-beta and tumor necrosis factor concentrations and outcome from neonatal gram-negative enteric bacillary meningitis. , 1989, The Pediatric infectious disease journal.

[26]  N. Rothwell,et al.  Cytokines and the nervous system II: actions and mechanisms of action , 1995, Trends in Neurosciences.

[27]  T. Barrett,et al.  Evidence for participation of the macrophage in Shiga-like toxin II-induced lethality in mice. , 1990, Microbial pathogenesis.

[28]  P. Sansonetti,et al.  Interleukin 1 is released by murine macrophages during apoptosis induced by Shigella flexneri. , 1994, The Journal of clinical investigation.

[29]  B. Redman,et al.  Phase II trial of recombinant interleukin-1β in patients with metastatic renal cell carcinoma , 1994 .

[30]  E. Barrett-Connor,et al.  Extraintestinal manifestations of shigellosis. , 1970, The American journal of gastroenterology.

[31]  R. Collins,et al.  Genetic dissection of susceptibility to audiogenic seizures in inbred mice. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[32]  T. Seki,et al.  Neurological manifestations of hemorrhagic colitis in the outbreak of Escherichia coli O157:H7 infection in Japan , 1993, Acta paediatrica.

[33]  L. Reed,et al.  A SIMPLE METHOD OF ESTIMATING FIFTY PER CENT ENDPOINTS , 1938 .

[34]  V. Jay,et al.  Experimental verocytotoxemia in rabbits , 1992, Infection and immunity.

[35]  S. Ashkenazi,et al.  Convulsions in childhood shigellosis. Clinical and laboratory features in 153 children. , 1987, American journal of diseases of children.

[36]  D. Goddard Phases of the Metabolism of Trichophyton Interdigitale Priestley , 1934 .